Statement Of Financial Position [Abstract]

Innate Pharma - Filing #2811003

Concept	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Statement of financial position [abstract]
Assets [abstract]
Intangible assets other than goodwill	—	—	—	—	416,000 EUR	—	1 556 EUR	—	—	—	—	—	—	—	—	—	—	—
Deferred tax assets	—	—	—	—	9 006 EUR	—	8 568 EUR	—	—	—	—	—	—	—	—	—	—	—
Trade and other receivables	—	—	—	—	66 111 EUR	—	52 445 EUR	—	—	—	—	—	—	48 241 EUR	—	—	—	—
Cash and cash equivalents	—	—	—	—	70 605 EUR	—	84 225 EUR	—	—	—	—	—	—	103 756 EUR	—	—	—	—
Assets	—	—	—	—	184 193 EUR	—	207 863 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities [abstract]
Equity [abstract]
Issued capital	—	—	—	—	4 044 EUR	—	4 011 EUR	—	—	—	—	—	—	—	—	—	—	—
Share premium	—	—	—	—	384 255 EUR	—	379 637 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity	384 255 EUR	4 044 EUR	495,000 EUR	329 323 EUR	51 901 EUR	7 570 EUR	54 151 EUR	379 637 EUR	272 213 EUR	58 103 EUR	4 011 EUR	819,000 EUR	219 404 EUR	107 440 EUR	456,000 EUR	52 809 EUR	375 220 EUR	3 978 EUR
Liabilities [abstract]
Trade and other payables	—	—	—	—	17 018 EUR	—	20 911 EUR	—	—	—	—	—	—	28 573 EUR	—	—	—	—
Deferred tax liabilities	—	—	—	—	9 006 EUR	—	8 568 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities	—	—	—	—	184 193 EUR	—	207 863 EUR	—	—	—	—	—	—	—	—	—	—	—